Skip to main content
OpenTrials
Completed

NCT Number: NCT05975450

Subcutaneous Abatacept in Renal Transplant Recipients

After a kidney transplant, patients take drugs called anti-rejection drugs (immunosuppressives) to prevent their bodies from rejecting the new kidney. At present it is not possible to have a successful transplant without these drugs. These drugs make it possible for a person who receives the transplant to accept the "foreign" kidney. Most patients who get a transplant need to take anti-rejection medications for the rest of their lives, or for as long as the kidney continues to work.

Researchers are looking to learn whether abatacept is as good as belatacept in preventing rejection, whether there are other benefits or harms associated with abatacept treatment, and possibly allows greater flexibility on patient's travel and time since abatacept is self-administered at home.

This study is being done to answer these questions:

Are weekly abatacept injections under the skin a safe and effective substitute for monthly belatacept intravenous (IV) infusions? and How well does the kidney function after switching from belatacept to abatacept?

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Kidney Transplant Recipient

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Emory Clinic, Atlanta, Georgia, United States

Loading trial locations.

About this study

This is a Phase I, open-label, prospective, single-arm single-center study to evaluate the feasibility, effectiveness, and safety of a regimen substituting subcutaneous abatacept early post-transplant in place of intravenous belatacept as an immunosuppressant in first-time renal transplant recipients.

There is a single arm in this study; the Investigational (abatacept) group. Participants will be assigned to a treatment regimen between 2 and 5 months after transplantation. The study drug will be administered until month 12 post-transplant; at that point, all participants will be transitioned to a physician-directed immunosuppressive regimen post-study.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Must be able to understand and provide informed consent.
  • Male or Female, 18-70 years of age at the time of enrollment (all races and ethnicities)
  • Negative crossmatch (virtual or physical) at the time of transplant
  • No less than 8 weeks, no more than 20 weeks post-transplant at enrollment
  • A first-time renal transplant who has been treated with belatacept from the time of transplant, receiving tacrolimus (target trough 3-5 ng/ml), mycophenolate mofetil (or mycophenolic acid or azathioprine), prednisone (also see exclusion criteria).
  • eGFR ≥ 40ml/min/m2 [using 2021 the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation].
  • Prior documented evidence of Epstein-Barr virus (EBV) seropositivity must be available.
  • Female study participants of childbearing potential must have a negative pregnancy test before enrollment.
  • Agreement to use contraception that is more than 80% effective.
  • Vaccines are current as per the Division of Allergy, Immunology, and Transplantation (DAIT) guidance for patients in transplant trials.
  • Study participants must have a negative purified protein derivative (PPD) or negative testing for tuberculosis using an approved Interferon Gamma Release Assay (IGRA) blood test, such as QuantiFERON®-Gold tuberculosis (TB) or T-SPOT®-TB assay. PPD or IGRA testing must be documented to have been performed within the 52 weeks before enrollment. Patients with latent TB may become eligible after completion of treatment.

Exclusion criteria

  • Inability or unwillingness of a study participant to give written informed consent or comply with the study protocol.
  • Recipient of previous organ transplant of any type.
  • Multi-organ transplant.
  • Calculated Panel Reactive Antibody (cPRA) >80 at the time of enrollment.
  • History of any episode of biopsy-proven Banff rejection (including borderline rejection or any grade of acute TCMR) before enrollment.
  • History of any malignancy including lymphoma within 5 years of enrollment. Study participants with curatively treated non-melanomatous skin cancer or curatively treated cervical carcinoma in situ may be enrolled.
  • Any past or current issue which in the opinion of the investigator may pose additional risks to the participant in the study, may interfere with the study participant's ability to comply with the study requirements, or may impact the quality or interpretation of the data obtained from the study.
  • Human immunodeficiency virus (HIV): individuals known to be HIV positive.
  • Hepatitis C virus (HCV): any study participant who receives a kidney from a seropositive or HCV RNA PCR-positive donor is ineligible. Any study participant who was HCV RNA PCR positive at transplant is ineligible. Any study participant with a history of HCV seropositivity or HCV infection who has not met the criteria for sustained spontaneous clearance or sustained viral response to therapy is ineligible.
  • Hepatitis B virus (HBV): Individuals with any of the following are NOT eligible:
  • Recipient or donor positive for hepatitis B surface antigen (HBsAg)
  • Recipient or donor positive for antibodies to hepatitis B core antigen (anti-HBc)
  • Recipient or donor is known to have had a positive HBV DNA PCR
  • Evidence of CMV viremia or clinical CMV infection at any time after transplant.
  • Kidney recipients who were CMV seronegative who received an organ from a CMV seropositive donor.
  • BK viremia of greater than 4.3 DNA log copies/ml (greater than 20,000 copies/ml) at any time post-transplant.
  • Active uncontrolled infection within 1 month of enrollment.
  • Clinically significant proteinuria (urinary protein/Cr ratio >1.0).
  • Receiving belatacept at a dose other than 5 mg/kg body weight.
  • Receiving mycophenolate mofetil at a dose of less than 1000 mg daily (or mycophenolic acid or azathioprine equivalent).
  • Receiving prednisone at a dose greater than 5 mg daily.
  • Presence of donor-specific antibody by Luminex single antigen bead assay.

Treatment and study plan

Abatacept 125Mg/Ml Syringe

Drug

Participants on a qualifying belatacept regimen (with low-dose tacrolimus, mycophenylate mofetil (MMF), and prednisone) will have their maintenance regimen changed from i.v. Belatacept to s.c. abatacept, which will continue through week 52 (month 12) post-transplant:

Costimulation blockade:

  • Abatacept 125 mg subcutaneous weekly

Other names: Orencia

Primary outcomes

  1. Number of Participants Who Are Compliant With Self-administration

    Time frame: Up to 12 months post-transplantation, an average of 8 months

    Compliance and self-administration will be measured using the abatacept administration logs and autoinjector accountability.

  2. Number of Participants Who Remain Free of Biopsy-proven Acute T-cell Mediated Rejection (aTCMR) or Antibody-mediated Rejection (ABMR) as Defined by Banff Criteria at or Before 12 Months After Transplantation.

    Time frame: Up to 12 months post-transplantation, an average of 8 months

    For-cause biopsies may be performed as dictated by the clinical team. A for-cause biopsy (i.e., graft dysfunction) may be performed in cases of increased serum creatinine, proteinuria, or other clinical symptoms at the discretion of the site Investigator.

  3. Number of Participants Presenting Serious Adverse Events

    Time frame: Up to 12 months post-transplantation, an average of 8 months

    Assessments of serious adverse events will be completed at each study visit from the time abatacept starts through 12 months post-transplant.

  4. Number of Participants With Serious Infections

    Time frame: Up to 12 months post-transplantation, an average of 8 months

    Any serious infection requiring hospitalization or prolonged therapy, including but not limited to treatment ≥ 20 days, will be documented.

  5. Number of Patients With Cytomegalovirus (CMV) Viremia Stratified by the Magnitude

    Time frame: Up to 12 months post-transplantation, an average of 8 months

    All subjects will be monitored for CMV infection by quantitative polymerase chain reaction (PCR) in the blood per the Emory Transplant Center standard of care protocol, CMV viremia stratified by count ≥35 but <10,000 or ≥ 10,000.

  6. Number of Patients With BK Viremia Stratified by the Magnitude

    Time frame: Up to 12 months post-transplantation, an average of 8 months

    Undetected, >0 but < 1,000, ≥ 1,000 but <10,000, or ≥ 10,000 - 100,000, ≥100,000 or stratified by log, which is reported as a result.

  7. Number of Participants Who Develop Any Malignancy

    Time frame: Up to 12 months post-transplantation, an average of 8 months

    Incidence of any malignancy, including Post-Transplant Lymphoproliferative Disorder (PTLD)

Secondary outcomes

  1. Number of Participants Experiencing the Composite Outcome of Death or Allograft Failure

    Time frame: Up to 12 months post-transplantation, an average of 8 months

    Death and/or allograft failure at or before 12 months after transplantation

  2. Number of Participants With Biopsy-proven Acute T-cell Mediated Cellular Rejection (BP-aTCMR)

    Time frame: Up to 12 months post-transplantation, an average of 8 months

    Incidence of biopsy-proven acute T-cell mediated cellular rejection (BP-aTCMR)

  3. Number of Participants Treated for Rejection

    Time frame: Up to 12 months post-transplantation, an average of 8 months

    The number of participants treated for rejection with any of the following: i) corticosteroids within 12 months, ii) T-cell depleting therapy within 12 months, iii) any other treatment for rejection within 12 months of transplantation

  4. Number of Participants Treated for Acute Rejection Due to Clinical Suspicion Rather Than BP-aTCMR or BP-aABMR Within 12 Months of Transplantation.

    Time frame: Up to 12 months post-transplantation, an average of 8 months

    For-cause biopsies may be performed as dictated by the clinical team. A for-cause biopsy (i.e., graft dysfunction) may be performed in cases of increased serum creatinine, proteinuria, or other clinical symptoms at the discretion of the site Investigator.

  5. Number of Participants With Biopsy-proven Active Antibody-mediated Rejection (BP-aABMR)

    Time frame: Up to 12 months post-transplantation, an average of 8 months

    For-cause biopsies may be performed as dictated by the clinical team. A for-cause biopsy (i.e., graft dysfunction) may be performed in cases of increased serum creatinine, proteinuria, or other clinical symptoms at the discretion of the site Investigator.

  6. Number of Participants With Changes in Allograft Biopsies for the 5 Categories of aTCMR Specified in the Banff Schema

    Time frame: Up to 12 months post-transplantation, an average of 8 months

    For-cause biopsies may be performed as dictated by the clinical team. A for-cause biopsy (i.e., graft dysfunction) may be performed in cases of increased serum creatinine, proteinuria, or other clinical symptoms at the discretion of the site Investigator.

  7. Time to Changes in Allograft Biopsies for the 5 Categories of aTCMR Specified in the Banff Schema

    Time frame: Up to 12 months post-transplantation, an average of 8 months

    Calculations will be made from the start of abatacept through to 12 months post-transplant. A for-cause biopsy (i.e., graft dysfunction) may be performed in cases of increased serum creatinine, proteinuria, or other clinical symptoms at the discretion of the site Investigator.

  8. Number of Participants Who Develop De-novo Donor Specific Antibody (DSA)

    Time frame: Up to 12 months post-transplantation, an average of 8 months

    Number of participants who develop de-novo DSA

  9. Estimated Glomerular Filtration Rate (eGFR)

    Time frame: Baseline and 12 months post-transplantation

    The eGFR will be calculated at the time abatacept is started and 12 months post-transplant

  10. Number of Days to Events [TCMR, ABMR, De-novo Specific Antibodies (DSA) Formation, Graft Loss].

    Time frame: Up to 12 months post-transplantation, an average of 8 months

    All events will be documented, and calculations will be made from the start of abatacept through 12 months post-transplant.

Sponsors and collaborators

Lead sponsor

Idelberto Badell

Other

Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

Registry information

Official study title

Early Substitution of Subcutaneous Abatacept for Belatacept as Costimulation Blockade to Minimize Calcineurin Inhibitors (CNI) Exposure After Kidney Transplantation

Acronym: RTB-016

Important dates

Study start
2023
Primary completion
2025
Study completion
2025
First posted
Aug 3, 2023
Registry last updated
Apr 3, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.